v25i2

The science of medicine is undergoing revolutionary change as genomics, big data and advanced technologies open whole new pathways for improving human health. The era of precision medicine is within grasp, meaning diagnoses, treatments and prognoses are based as much on the disease as the genetic, environmental and lifestyle factors that affect patient health. This has enormous potential for developing new treatments that lead to better health outcomes. HKUMed is at the forefront of this horizon. With a new injection of support from the Hong Kong government, new facilities and new and renewed collaborations with some of the world’s leading scientific institutes, HKUMed is positioning itself to make significant impacts that will reverberate across the field of medicine. Drawing on our world-leading strengths in emerging infectious diseases, cancers and stem cell biology, the Faculty is leading five new major research programmes that will significantly deepen our understanding of disease and human responses to viruses and cancers, and develop cutting-edge treatments. Some of the first outcomes are expected to be an Immune Report Card for patients, universal influenza vaccine options, new technology for regenerative medicine, new biomarkers for several cancers, and antiviral treatments for influenza and HIV. These will be developed with leading experts in a range of disciplines from top research institutions in the UK, Germany, Canada, the US and Mainland China, as well as Hong Kong. Some HK$400 million will be provided to each programme over five years through the government’s Health@InnoHK and AIR@InnoHK initiatives, which aim to develop Hong Kong into a hub for global research collaboration – a vision in which HKUMed will play a central role. Additional government funds have also been earmarked for technology transfer, State Key Laboratories (the Faculty is home to four) and enhancement of campus facilities. “HKUMed has the expertise, international standing and, most importantly, the ambition to continue leading at the forefront of modern medicine,” said the Dean, Professor Gabriel Leung. “With this injection of new funding support, we will have the means to produce ‘moonshots’ that can bring tremendous healthcare benefits to all of society, in Hong Kong, the nation and around the world.” The “moonshot” trajectory starts here. 醫學科學和科技正經歷革命性改變，皆因基因組 學、大數據及先進科技為改善人類健康開創新領域。 精準醫學的年代即將降臨，意味著除了疾病本身，我 們可以依據遺傳學、環境及生活習慣等因素去診斷、 治療以至預測病變，在研發改善健康的嶄新治療方 面，具有莫大潛能。香港大學李嘉誠醫學院（醫學 院）高瞻遠矚，正在該新領域前沿，成為多項研究的 先驅。 醫學院獲得香港政府新一輪資助，添置了新設 施，又與國際知名科學研究所達成全新或更新合作協 議，進一步鞏固港大醫學院的地位，使我們的研究成 果在醫學界引發更大廻響。 憑藉醫學院於新發傳染病、癌症及幹細胞生物 學方面領先國際的研究，我們現正進行五項全新的重 要研究，將有助我們加深對疾病、人體對病毒及癌細 胞反應的理解，並研發最新的治療方法。預計首輪成 果將會包括推出「病人免疫記錄卡」、通用流感疫苗、 再生醫學新科技、多種癌症的新生物標記，以及流感 及愛滋病的抗病毒治療。為此，醫學院與英國、德 國、加拿大、美國、中國內地及香港的頂尖研究機構 和多個學科的知名專家合作研究。 未來五年，政府將會透過 Health@InnoHK 和 AIR@InnoHK 創新平台，向每項計劃投入約四億港 元，旨在把香港發展成為全球科研合作中心，而港大 醫學院將會在這個宏圖裡扮演重要的主導角色。此 外，政府亦預留額外資金資助科技轉移、學院裡的四 間國家重點實驗室，以及提升學院設施之用。 醫學院院長梁卓偉教授表示：「港大醫學院不但 擁有多元化的專業優勢、崇高的國際地位，更具備持 續領導現代醫學研究的決心。政府是次撥款，讓我們 可以進行更多具前瞻性的研究，為香港、國家甚至全 球醫療健康帶來莫大裨益。」 創新大道，由此啟航。 03 Medical Faculty News